FDA Clears TriSalus' TriNav Advance, Expanding PEDD Portfolio for Liver Embolization
TLSI has more than doubled off its 52-week low of $2.2.
Summary
TriSalus received FDA 510(k) clearance for TriNav Advance, a new device in its Pressure-Enabled Drug Delivery portfolio. The clearance expands the company's addressable market beyond liver embolization to a broader range of procedures, and management plans a limited market release in the coming weeks. This is a meaningful regulatory milestone for a company with a market cap around $300 million and declining revenue, as it adds a third FDA-cleared device and could drive adoption. The device's compatibility with standard microcatheters may lower barriers for interventional radiologists. Watch for initial sales data from the limited release to gauge commercial traction.
Updates
· Seeking Alpha — TriSalus shares rose about 16% in premarket trading following the clearance.
At the time of this announcement, TLSI was trading at $4.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $303.6M. The 52-week trading range was $2.20 to $7.95. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.